Related Experiment Video

Updated: Jul 10, 2026

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

The MDM-2 antagonist nutlin-3 promotes the maturation of acute myeloid leukemic blasts

Paola Secchiero1, Carlotta Zerbinati, Elisabetta Melloni

  • 1Department of Morphology and Embryology, University of Ferrara, Ferrara, Italy. sccpla@unife.it

Neoplasia (New York, N.Y.)
|November 1, 2007
PubMed

Insights

Nutlin-3, a MDM-2 inhibitor, induces apoptosis and myeloid maturation in acute myeloid leukemia (AML) cells, even those with p53 deletions. It may offer a novel therapeutic strategy for AML, potentially combined with TRAIL.

Area of Science:

  • Oncology
  • Molecular Biology
  • Hematology

Background:

  • Acute myeloid leukemia (AML) is a heterogeneous hematologic malignancy.
  • The MDM-2/p53 pathway is a critical regulator of cell fate.
  • Targeting MDM-2 with inhibitors like Nutlin-3 is a potential therapeutic strategy for AML.

Purpose of the Study:

  • To investigate the effects of Nutlin-3 on AML blasts, focusing on apoptosis and myeloid differentiation.
  • To explore the role of the p53 pathway and E2F1 in Nutlin-3-induced maturation.
  • To evaluate the potential synergistic effects of Nutlin-3 with TNF-related apoptosis-inducing ligand (TRAIL).

Main Methods:

  • Treatment of primary AML blasts and HL-60 cell lines with Nutlin-3.
  • Flow cytometry analysis of CD11b and CD14 surface antigens.
  • Morphologic examination for myeloid maturation.
  • Gene knockdown using small interfering RNA (siRNA) for E2F1.
  • Combination treatment with Nutlin-3, TNF-alpha, and TRAIL.

Main Results:

  • Nutlin-3 induced variable apoptosis and promoted myeloid maturation in AML blasts.
  • Maturation occurred independently of p53 status, including in p53-deleted samples and cell lines.
  • Nutlin-3-induced maturation in HL-60 cells was associated with E2F1 induction and counteracted by E2F1 knockdown.
  • Nutlin-3 potentiated TRAIL-induced maturation but not its proapoptotic effect.

Conclusions:

  • Nutlin-3 exhibits a novel therapeutic potential for both p53 wild-type and p53-deficient AML.
  • The maturational effects of Nutlin-3 are partly mediated by E2F1.
  • Combination therapy with Nutlin-3 and TRAIL warrants further investigation for AML treatment.
Keywords:
Acute myeloid leukemiaHL-60 cellsapoptosisp53 pathwaysurface antigens

More Related Videos

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome06:39

Use of Hematopoietic Stem Cell Transplantation to Assess the Origin of Myelodysplastic Syndrome

Published on: October 3, 2018

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the daughter...
Differentiation of Common Myeloid Progenitor Cells01:15

Differentiation of Common Myeloid Progenitor Cells

Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...